[go: up one dir, main page]

EE200100323A - (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena - Google Patents

(Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena

Info

Publication number
EE200100323A
EE200100323A EEP200100323A EEP200100323A EE200100323A EE 200100323 A EE200100323 A EE 200100323A EE P200100323 A EEP200100323 A EE P200100323A EE P200100323 A EEP200100323 A EE P200100323A EE 200100323 A EE200100323 A EE 200100323A
Authority
EE
Estonia
Prior art keywords
hetero
aryl
preparation
protease inhibitors
bicyclic heteroaryl
Prior art date
Application number
EEP200100323A
Other languages
English (en)
Inventor
Arthur Allen Darin
M. Hataye Jason
N. Hruzewicz Witold
Kolesnikov Aleksandr
Laurence Mackman Richard
Rai Roopa
R. Spencer Jeffrey
J. Verner Erik
B. Young Wendy
Original Assignee
Axys Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceuticals, Inc. filed Critical Axys Pharmaceuticals, Inc.
Publication of EE200100323A publication Critical patent/EE200100323A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100323A 1998-12-18 1999-12-17 (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena EE200100323A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11300798P 1998-12-18 1998-12-18
PCT/US1999/030302 WO2000035886A2 (en) 1998-12-18 1999-12-17 (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

Publications (1)

Publication Number Publication Date
EE200100323A true EE200100323A (et) 2002-08-15

Family

ID=22347074

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100323A EE200100323A (et) 1998-12-18 1999-12-17 (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena

Country Status (20)

Country Link
US (1) US6867200B1 (et)
EP (1) EP1140859A2 (et)
JP (1) JP2002532479A (et)
KR (1) KR20010086119A (et)
CN (1) CN1344256A (et)
AU (1) AU779117B2 (et)
BR (1) BR9916363A (et)
CA (1) CA2355249A1 (et)
CZ (1) CZ20012006A3 (et)
EA (1) EA200100675A1 (et)
EE (1) EE200100323A (et)
HU (1) HUP0104987A3 (et)
IL (1) IL143801A0 (et)
NO (1) NO20012980L (et)
NZ (1) NZ512375A (et)
PL (1) PL349192A1 (et)
SK (1) SK7972001A3 (et)
TR (1) TR200102533T2 (et)
UA (1) UA70976C2 (et)
WO (1) WO2000035886A2 (et)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6465503B2 (en) * 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
EP1364960A4 (en) 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
EP1408963A1 (en) * 2001-07-09 2004-04-21 Axys Pharmaceuticals, Inc. 2- 5-(5-CARBAMIMIDOYL-1 i H /i -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS
IL159858A0 (en) 2001-07-27 2004-06-20 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1425015A4 (en) * 2001-08-20 2004-12-15 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS ANTITHROMBOTIC AGENTS
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
AU2003215158A1 (en) * 2002-02-13 2003-09-04 Axys Pharmaceuticals, Inc. 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
US6867320B2 (en) 2002-02-21 2005-03-15 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
CN101172983A (zh) 2002-03-20 2008-05-07 麦它波莱克斯股份有限公司 取代的苯乙酸
AU2002368133A1 (en) * 2002-07-29 2004-02-16 Shizuoka Coffein Co., Ltd. 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
RU2328483C2 (ru) 2002-08-29 2008-07-10 Мерк Энд Ко., Инк. Индолы, обладающие противодиабетической активностью
DK1569912T3 (en) * 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
WO2004062661A1 (en) * 2003-01-08 2004-07-29 Axys Pharmaceuticals, Inc. 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7199259B2 (en) 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN101031539A (zh) 2003-08-14 2007-09-05 旭化成制药株式会社 取代的芳基链烷酸衍生物及其用途
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EP1751120A4 (en) 2004-05-25 2010-05-05 Metabolex Inc SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND MANUFACTURING METHOD THEREFOR
CN102417484A (zh) * 2004-06-02 2012-04-18 法莫西克立克斯公司 因子VIIa抑制剂
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
MXPA06014066A (es) * 2004-06-02 2007-02-15 Pharmacyclics Inc Inhibicion de factor viia.
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR101178747B1 (ko) * 2004-09-30 2012-09-03 다케다 야쿠힌 고교 가부시키가이샤 프로톤 펌프 저해제
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7714131B2 (en) 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
CA2669736C (en) * 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
JPWO2007114213A1 (ja) 2006-03-30 2009-08-13 旭化成ファーマ株式会社 置換二環式環状誘導体及びその用途
WO2008150470A1 (en) 2007-05-31 2008-12-11 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
US20100215837A1 (en) * 2007-06-19 2010-08-26 Rhodri Evans Process for making an electrode, an electrode and a battery comprising the electrode
CN101861335B (zh) 2007-10-16 2013-09-04 环状药物公司 凝血因子viia调节剂的制造、组合物和用途
US8334314B2 (en) 2008-04-28 2012-12-18 Asahi Kasei Pharma Corporation Phenylpropionic acid derivative and use thereof
ES2408159T3 (es) 2008-06-11 2013-06-18 Shionogi & Co., Ltd. Compuestos de oxicarbamoilo y su utilización
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
CN101654427B (zh) * 2008-08-19 2012-12-05 信谊药厂 抗凝化合物、组合物及其用途
KR101354418B1 (ko) * 2009-07-30 2014-01-23 단국대학교 산학협력단 형광 탐지자 및 이의 제조 방법
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI541241B (zh) * 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
US9493436B2 (en) 2011-04-26 2016-11-15 Indiana University Research And Technology Corporation Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of Mycobacterium tuberculosis
JP6259451B2 (ja) 2012-06-15 2018-01-10 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
CN107109227B (zh) * 2014-09-30 2021-05-04 光学转变公司 紫外光吸收剂
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
EP3310441B1 (en) 2015-06-18 2020-07-29 89Bio Ltd. 1, 4-substituted piperidine derivatives
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
KR102547771B1 (ko) * 2015-11-09 2023-06-26 고려대학교 산학협력단 4-치환된-2-(5-치환된-1h-인돌-2-일)페놀 유도체, 그 제조방법 및 이를 포함하는 세포 증식 및 전이 억제용 약학 조성물
SMT202200369T1 (it) 2015-11-19 2022-11-18 Incyte Corp Composti eterociclici come immunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SG10202005790VA (en) 2015-12-22 2020-07-29 Incyte Corp Heterocyclic compounds as immunomodulators
ES2906460T3 (es) * 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
CN105884673B (zh) * 2016-06-03 2018-05-11 温州大学 一种吲哚衍生物的合成方法
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EA038972B1 (ru) 2016-07-30 2021-11-16 Бристол-Маерс Сквибб Компани Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MA46188A (fr) 2016-09-09 2019-07-17 Bristol Myers Squibb Co Composés indole substitués par pyridyle
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
PL3558990T3 (pl) 2016-12-22 2022-12-19 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
ES2909401T3 (es) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
US20210253593A1 (en) 2017-11-14 2021-08-19 Bristol-Myers Squibb Company Substituted indole compounds
MX2020006093A (es) 2017-12-15 2020-08-24 Bristol Myers Squibb Co Compuestos de indol eter sustituidos.
PE20210129A1 (es) 2017-12-18 2021-01-19 Bristol Myers Squibb Co Compuestos de 4-azaindol
BR112020011788A2 (pt) 2017-12-19 2020-11-24 Bristol-Myers Squibb Company compostos 6-azaindóis
CN111491930B (zh) 2017-12-19 2023-09-26 百时美施贵宝公司 可用作tlr抑制剂的经取代的吲哚化合物
ES2922174T3 (es) 2017-12-19 2022-09-09 Bristol Myers Squibb Co Compuestos de indol sustituidos con amida útiles como inhibidores de TLR
KR102714788B1 (ko) 2017-12-20 2024-10-08 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미노 인돌 화합물
US11299501B2 (en) 2017-12-20 2022-04-12 Bristol-Myers Squibb Company Diazaindole compounds
JP7291707B2 (ja) 2017-12-20 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アリールおよびヘテロアリール置換されたインドール化合物
UA128453C2 (uk) 2018-03-30 2024-07-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
WO2020072580A1 (en) * 2018-10-02 2020-04-09 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
EP3870589B1 (en) 2018-10-24 2023-09-06 Bristol-Myers Squibb Company Substituted indole dimer compounds
KR102839382B1 (ko) 2018-10-24 2025-07-25 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 및 인다졸 화합물
EP3965888B1 (en) 2019-05-09 2024-08-21 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN115175734B (zh) 2019-09-30 2024-04-19 因赛特公司 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
EP4165034A1 (en) 2020-06-11 2023-04-19 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
CN116283896B (zh) * 2022-09-07 2024-10-29 广东晨康生物科技有限公司 一种具有pd-l1抑制活性的联苯类化合物及其用途
CN117430525A (zh) * 2023-03-01 2024-01-23 中化学科学技术研究有限公司 席夫碱配体及其制备方法和应用
CN120904199A (zh) * 2025-09-30 2025-11-07 上海泽德曼医药科技有限公司 具有稠环结构的化合物及其在医药上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2273841A1 (fr) * 1974-06-05 1976-01-02 Labaz Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle
CH618639A5 (et) * 1976-06-04 1980-08-15 Ciba Geigy Ag
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4623379A (en) * 1984-12-14 1986-11-18 Fmc Corporation Plant growth and development modification using 2-(2-oxycarbonylphenyl)benzimidazole derivatives
JPS63166588A (ja) * 1986-12-27 1988-07-09 Kanzaki Paper Mfg Co Ltd クロメノ化合物およびクロメノ化合物を用いた感熱記録体
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
US6255091B1 (en) * 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
US5942532A (en) * 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
US6150379A (en) 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
WO1999026933A1 (en) 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants

Also Published As

Publication number Publication date
NO20012980D0 (no) 2001-06-15
UA70976C2 (uk) 2004-11-15
WO2000035886A2 (en) 2000-06-22
US6867200B1 (en) 2005-03-15
EP1140859A2 (en) 2001-10-10
PL349192A1 (en) 2002-07-01
CZ20012006A3 (cs) 2002-03-13
HUP0104987A3 (en) 2002-09-30
AU779117B2 (en) 2005-01-06
BR9916363A (pt) 2001-12-11
SK7972001A3 (en) 2002-06-04
HUP0104987A2 (hu) 2002-07-29
NO20012980L (no) 2001-08-01
IL143801A0 (en) 2002-04-21
KR20010086119A (ko) 2001-09-07
CA2355249A1 (en) 2000-06-22
TR200102533T2 (tr) 2006-06-21
EA200100675A1 (ru) 2001-12-24
NZ512375A (en) 2003-11-28
WO2000035886A3 (en) 2000-10-26
CN1344256A (zh) 2002-04-10
JP2002532479A (ja) 2002-10-02
AU2711500A (en) 2000-07-03

Similar Documents

Publication Publication Date Title
EE200100323A (et) (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
DE60024631T2 (de) Biaryl-harnstoff-derivate
EE200100185A (et) Asendatud fenüülderivaadid, nende valmistamine jakasutamine
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
ATE256123T1 (de) Pyrimidonderivate
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
DK1165516T3 (da) Heterocyklisk urinstof og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK0946512T3 (da) 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer
DK1163244T3 (da) Thienopyrimidinforbindelser, fremstilling og anvendelse heraf
DK1198453T3 (da) N-(indolcarbonyl-)piperazinderivater
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
DE69900356D1 (de) Nitro-Isoharnstoffderivate
PT1173187E (pt) Preparacoes combinadas compreendendo derivados de antraciclina
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
DK1218383T3 (da) Biocykliske imidazo-5-yl-aminoderivater
DK1202953T3 (da) Substituerede 2-dialkylaminoalkylbiphenylderivater
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine